Nivolumab and pembrolizumab, two monoclonal antibodies targeting programmed cell death protein 1 (PD-1), have shown encouraging efficacy and safety for the treatment of sorafenib-experienced HCC patients [6,7]. The gene discussed is PDCD1; the disease is hepatocellular carcinoma.